Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Hidradenitis suppurativa
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms SMASH
- 19 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2017 New trial record